NVAX
Low · 37/100Novavax, Inc.
Healthcare · Biotechnology
- 28% short float
- 9 days to cover
- coiled 2d
- fresh catalyst
Key Statistics
ⓘ Short interest from FINRA via Yahoo Finance (biweekly, ~2–3 week lag). Cost-to-borrow & shares-available from the Interactive Brokers feed via iBorrowDesk — the free proxy for utilization. Daily short-sale volume from the FINRA consolidated daily file (2026-07-02) — the fresh short pulse vs the ~2-week-lagged biweekly SI. SEC FTD files are aggregate balances and can lag the trading setup. Price, volume, and technicals from market data. Last updated: Jul 6, 02:17 PM
% of free float currently sold short
Shares short ÷ avg daily volume
Freely tradeable shares — smaller = more volatile
Cost-to-borrow + availability — the utilization proxy (IBKR feed)
Current volume ÷ 20-day average volume
RSI(14) + price vs. 50/200-day moving averages
Call / Put open interest ratio (gamma fuel)
Short volume ÷ total volume (FINRA daily) — the fresh short pulse vs the biweekly SI
What to Watch
- ●Short interest at 27.61% of float — elevated level
- ●9.1 days to cover — shorts would need sustained volume to exit
- ○141.47M share float — large float dampens squeeze dynamics
- ○Borrow data n/a — easy to borrow: little borrow-side pressure
- ○Volume 0.2× normal — quiet — awaiting catalyst
- ●Price above 50-day MA — momentum shifted bullish, shorts face stop-loss pressure
Squeeze Conditions Checklist
Catalyst · fuel needs ignition
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash